Heart Device Approval Might Change The Case For Investing In Abbott Stock (ABT)
Heart Device Approval Might Change The Case For Investing In Abbott Stock (ABT) Simply Wall St
Covered in this story
Analyst targets on Abbott Laboratories
- Mizuho: $103 → $115 by Oct 2027 · Neutral via Investing.com
- BTIG: $103 → $125 by Oct 2027 · Buy via Investing.com
- StoneX: $103 → $120 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 41 stories mentioning Abbott Laboratories, the earliest published 6 May 2017.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.